NCT00120081View on ClinicalTrials.gov

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Hookworm Infection
Interventions
BIOLOGICAL

Na-ASP-2/Alhydrogel Hookworm Vaccine

The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.

BIOLOGICAL

Saline placebo

Inactive saline placebo control

Trial Locations (1)

20037

George Washington University Medical Center, Washington D.C.

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Baylor College of Medicine

OTHER

NCT00120081 - Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection | Biotech Hunter | Biotech Hunter